Allogene Therapeutics (ALLO) Profit After Tax (2019 - 2025)
Historic Profit After Tax for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$41.4 million.
- Allogene Therapeutics' Profit After Tax rose 3755.0% to -$41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 8808.88%. This contributed to the annual value of -$257.6 million for FY2024, which is 2129.01% up from last year.
- As of Q3 2025, Allogene Therapeutics' Profit After Tax stood at -$41.4 million, which was up 3755.0% from -$50.9 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Profit After Tax peaked at -$33.0 million during Q1 2021, and registered a low of -$1.6 billion during Q4 2023.
- In the last 5 years, Allogene Therapeutics' Profit After Tax had a median value of -$70.9 million in 2021 and averaged -$251.3 million.
- Per our database at Business Quant, Allogene Therapeutics' Profit After Tax tumbled by 13809.48% in 2022 and then skyrocketed by 9631.65% in 2024.
- Over the past 5 years, Allogene Therapeutics' Profit After Tax (Quarter) stood at -$903.3 million in 2021, then tumbled by 36.72% to -$1.2 billion in 2022, then fell by 26.49% to -$1.6 billion in 2023, then skyrocketed by 96.32% to -$57.5 million in 2024, then increased by 28.06% to -$41.4 million in 2025.
- Its Profit After Tax stands at -$41.4 million for Q3 2025, versus -$50.9 million for Q2 2025 and -$59.7 million for Q1 2025.